Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $9.9050 (-3.97%) ($9.9050 - $9.9050) on Fri. Apr. 16, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.95% (three month average) | RSI | 56 | Latest Price | $9.9050(-3.97%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD advances 1.5% a day on average for past five trading days. | Weekly Trend | FOLD advances 1% a week on average for past two weeks. | Market Behavior | Value stock rally for large cap. Normal for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IBB(57%) IWO(53%) IWM(50%) XBI(50%) IWC(49%) | Factors Impacting FOLD price | FOLD will decline at least -2.475% in a week (0% probabilities). VIXM(-30%) VXX(-14%) UUP(-11%) UNG(-6%) IGOV(-6%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -2.475% (StdDev 4.95%) | Hourly BBV | -1.4 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $9.75(1.59%) | 10 Day Moving Average | $9.62(2.96%) | 20 Day Moving Average | $9.69(2.22%) | To recent high | -54.6% | To recent low | 7.7% | Market Cap | $2.558b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |